Anavex Life Sciences’ year-to-date stock performance.
Anavex Life Sciences: “…It is, indeed, a spec.”
Sarepta Therapeutics’ year-to-date stock performance.
Sarepta Therapeutics: “…It is troubling, I don’t want to be there.”
Viking Therapeutics’ year-to-date stock performance.
Viking Therapeutics: “I want you to sell Viking Therapeutics and roll it into Viking Holdings.”
Transocean’s year-to-date stock performance.
Transocean: “No, no, no. I do not dig RIG.”
DuPont de Nemours’ year-to-date stock performance.
DuPont de Nemours: “I say you hold on to DuPont, it’s very cheap versus the rest of the group.”
Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.
Questions for Cramer?
Call Cramer: 1-800-743-CNBC
Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money Twitter – Jim Cramer Twitter – Facebook – Instagram
Questions, comments, suggestions for the “Mad Money” website? [email protected]